Evidence map›Paper›PMID 35808894›Full record

ArticleThoracic cancer2022

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.

Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, Takuya Yamazaki, Sawana Ono, Hiromi Tomono, Takayuki Suyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto and 15 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 1 country.

Kazumasa AkagiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hirokazu TaniguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0003-2414-8344
Minoru FukudaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-5321-1843
Takuya YamazakiDepartment of Radiology, Nagasaki University Hospital, Nagasaki, Japan.
Sawana OnoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiromi TomonoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Takayuki SuyamaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Midori ShimadaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroshi GyotokuDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Shinnosuke TakemotoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroyuki YamaguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yosuke DotsuDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo, Japan.
Hiroaki SenjuDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo, Japan.
Hiroshi SodaDepartment of Respiratory Medicine, Sasebo City General Hospital, Sasebo, Japan.ORCID 0000-0003-4993-1837
Takashi MizowakiDepartment of Radiology, Sasebo City General Hospital, Sasebo, Japan.
Yoshio MonzenDepartment of Radiology, Sasebo City General Hospital, Sasebo, Japan.
Takaya IkedaDepartment of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Seiji NagashimaDepartment of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Yutaro TasakiDepartment of Radiology, Nagasaki University Hospital, Nagasaki, Japan.
Daisuke NakamuraDepartment of Radiology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Kazutoshi KomiyaDepartment of Respiratory Medicine, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.
Katsumi NakatomiDepartment of Respiratory Medicine, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.
Eisuke SasakiDepartment of Respiratory Medicine, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.
Koichi HirakawaDepartment of Radiology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nagasaki University · JPSasebo City General Hospital · JPNagasaki Medical Center · JPNational Hospital Organization · JPNagasaki University Hospital · JPNagasaki Prefectural Shimabara High School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEtoposide plus cisplatin (EP) combined with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard treatment strategy for unresectable limited-disease (LD) small cell lung cancer (SCLC), which has remained unchanged for over two decades. Based on a previous study that confirmed the non-inferiority of amrubicin (AMR) plus cisplatin (AP) when compared with EP for extensive-disease (ED) SCLC, we have previously conducted a phase I study assessing AP with concurrent TRT (2 Gy/time, once daily, 50 Gy in total) for LD-SCLC therapy. Our findings revealed that AP with concurrent TRT could prolong overall survival to 39.5 months with manageable toxicities. Therefore, we plan to conduct a phase I study to investigate and determine the effect of AP combined with AHTRT, recommended dose (RD), maximum tolerated dose (MTD), and dose-limiting toxicity (DLT) of AP in patients with LD-SCLC.

methodsTreatment-naive patients with LD-SCLC, age between 20 and 75 years, who had a performance status of 0 or 1 and adequate organ functions will be enrolled. For chemotherapy, cisplatin 60 mg/m DISCUSSION: Based on our previous study, the initial dose of AMR 25 mg/m

Indexed as

ChemoradiotherapyLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAnthracyclinesCisplatinClinical Trials, Phase I as TopicEtoposideHumansMiddle AgedYoung AdultamrubicinAnthracyclinesCisplatinEtoposideamrubicinchemotherapyradiotherapysmall cell lung cancer

Identifiers

PMID35808894
PMCPMC9376170
OpenAlexW4284989742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.